Study guide

1.12 Microdeletion Syndromes (22q11.2, Williams, and Related)

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.12 Microdeletion Syndromes (22q11.2, Williams, and Related)

Key Takeaways Explain This Topic AI

22q11.2 deletion syndrome (DiGeorge/VCFS spectrum) classically combines conotruncal cardiac defects, palatal anomalies, hypocalcemia/hypoparathyroidism, immune deficiency, and learning/psychiatric vulnerability

Williams syndrome is caused by a contiguous gene deletion at 7q11.23 including ELN, producing supravalvular aortic stenosis, connective-tissue findings, hypercalcemia risk, and a characteristic social/cognitive profile

Most classic 22q11.2 and Williams deletions are de novo, but parental testing still matters because inherited deletions change recurrence risk dramatically

Chromosomal microarray (CMA) is the usual first-line genome-wide CNV test; FISH can confirm a known targeted deletion but will miss deletions outside the probe’s target

Microdeletion counseling requires systems-based surveillance (cardiac, calcium/immune, development) rather than a single-organ narrative

Last updated: August 2026

1.12 Microdeletion Syndromes (22q11.2, Williams, and Related)

Quick Answer: Contiguous-gene microdeletions remove multiple neighboring genes. For CGC boards, master 22q11.2 deletion (cardiac–palate–calcium–immune–learning) and Williams syndrome (7q11.23, ELN) (supravalvular AS, hypercalcemia, cocktail-party personality). Most are de novo ; diagnose with CMA (genome-wide) and use FISH when you need a targeted assay—not as a substitute for unknowing genome-wide CNV detection.

Standard karyotype resolution often misses these deletions. That historical gap is why “normal karyotype + suggestive phenotype” still triggers microarray thinking.

Contiguous Gene Logic

A microdeletion is a chromosomal deletion too small for reliable detection on routine banding but large enough to remove multiple genes. Phenotype reflects the sum of haploinsufficient genes in the interval (plus modifier effects). This is why features cluster into recognizable syndromes rather than single-gene Mendelian patterns.

  • Concept Exam application
  • Contiguous gene syndrome Multi-system phenotype from one deletion event
  • Variable expressivity Same deletion, different severity—counsel the range
  • Incomplete ascertainment Mild cases diagnosed in adulthood (e.g., 22q psychiatric/learning presentations)
  • Recurrence Usually de novo; parental carrier/deletion status changes risk
  • 22q11.2 Deletion Syndrome (DiGeorge / VCFS Spectrum)

Historical names— DiGeorge syndrome , velocardiofacial syndrome (VCFS) , Shprintzen syndrome—largely describe the same 22q11.2 deletion continuum. Use the genomic name in counseling while recognizing older labels in records.

Key Clinical Features

  • System Findings
  • Cardiac Conotruncal defects: tetralogy of Fallot, interrupted aortic arch type B, truncus arteriosus, VSD
  • Palate / ENT Velopharyngeal insufficiency, cleft palate/submucous cleft, hypernasal speech
  • Endocrine Hypoparathyroidism → hypocalcemia (neonatal seizures possible)

Immune Thymic hypoplasia → T-cell immunodeficiency; infection risk; vaccine/live-vaccine considerations with immunology

Craniofacial Hooded eyelids, squared nasal tip, ear anomalies (variable; avoid over-reliance on “looks”)

Development / neuro Learning disabilities, ADHD, autism features; later psychiatric risk including schizophrenia-spectrum illness

Other Renal anomalies, feeding issues, hearing loss, growth concerns

A durable mnemonic still seen in teaching is CATCH-22 (Cardiac, Abnormal facies, Thymic, Cleft, Hypocalcemia)—useful as a checklist, not a requirement that every letter be present.

Inheritance and Recurrence

~90%+ of classic deletions are de novo .

Autosomal dominant transmission occurs when a parent carries the deletion (often milder or differently ascertained).

After a child is diagnosed, offer parental testing . If a parent is deleted, recurrence approaches 50% each pregnancy; if both parents test negative, residual risk is mainly rare germline mosaicism—counsel as low but not absolute zero.

Prenatal vs Postnatal Counseling

Prenatal: conotruncal cardiac defect ± cleft polyhydramnios/palate clues, or CMA/NIPT CNV findings → discuss multi-system involvement, surgical pathways, calcium/immune issues, and developmental supports. Postnatal: newborn hypocalcemia, feeding, cardiac surgery planning, immunology labs, early intervention. Adolescent/adult sessions often reopen psychiatric and reproductive counseling.

Williams Syndrome (7q11.23 Deletion)

Williams syndrome is a contiguous deletion at 7q11.23 that includes ELN (elastin). ELN haploinsufficiency drives much of the arteriopathy.

Domain Essentials

Cardiovascular Supravalvular aortic stenosis (SVAS) ; pulmonary stenosis; risk of other arterial stenoses; hypertension surveillance

Calcium Idiopathic infantile hypercalcemia possible; dietary/monitoring counseling

Facies / connective tissue Periorbital fullness, stellate iris pattern in some, full lips/cheeks; soft skin, joint laxity

Growth Failure to thrive in infancy; short adult stature common

Cognition / behavior Strengths in verbal/social engagement (“cocktail party” personality); weakness in visuospatial construction; anxiety common

Endocrine / other Hypothyroidism, diabetes risk later; hyperacusis

Inheritance: usually de novo ; rare parent-to-child transmission. Parental studies still indicated after diagnosis.

Related Microdeletion / Microduplication Context (Board Awareness)

Without turning this section into an encyclopedia, recognize that CMA commonly surfaces other recurrent CNVs counselors discuss:

  • Region / condition Why it appears on exams
  • 16p11.2 CNVs Neurodevelopmental phenotypes; variable expressivity
  • 1p36 deletion Distinctive craniofacial features, developmental disability, cardiac anomalies
  • 17p11.2 (Smith-Magenis) Behavioral phenotype, sleep disturbance, RAI1-related mechanisms
  • Reciprocal duplications (e.g., 22q11.2 dup) Often milder/variable vs deletion; still counsel carefully

The principle is the same: dosage-sensitive genes + variable expressivity + usually de novo with parental testing exceptions.

CMA vs FISH: Diagnostic Strategy

Test What it does well Limits

Chromosomal microarray (CMA) Genome-wide detection of deletions/duplications at kilobase–megabase resolution; first-line for many congenital anomaly / developmental indications Does not detect balanced rearrangements; may reveal VOUS; methylation/imprinting not assessed

FISH Fast, targeted confirmation of a known locus (e.g., 22q11.2 probe) when phenotype is classic or for family studies of a known deletion Will miss deletions outside the probe target; not a genome-wide screen

Karyotype Large aneuploidy/rearrangements, mosaicism (to a point) Misses most microdeletions

CGC trap: Ordering FISH for “developmental delay, unknown cause” can falsely reassure if the probe set does not cover the causative CNV. Conversely, once CMA identifies a 22q11.2 deletion, FISH or another targeted method may be used for rapid parental testing or reflex confirmation depending on laboratory workflow.

NIPT may flag some large CNVs with lower positive predictive value than for common trisomies—abnormal CNV screens still need diagnostic confirmation (CMA/karyotype pathway as indicated).

Counseling Structure for Contiguous Gene Syndromes

Explain deletion of multiple genes in accessible language (a missing segment, not “one broken gene” only).

Map organ-system surveillance to the specific syndrome (echo, calcium, immunology for 22q; cardiology and calcium for Williams).

Address developmental and psychiatric natural history without fatalism—supports change outcomes.

Clarify inheritance : probable de novo, but test parents before quoting 50% vs near-population recurrence.

Distinguish test capability : CMA finds unknown CNVs; FISH answers a targeted question.

Microdeletion fluency also prevents misclassifying these phenotypes as isolated single-gene disease or as full aneuploidy when the karyotype is normal—an essential Domain 1C discrimination skill.